

## Disclosures

### Personal Commercial (10)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Alexion Pharmaceuticals, Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Boehringer Ingelheim Pharmaceuticals, Inc	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Janssen Pharmaceuticals, Inc	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Arrhythmias and Clinical EP</i>
Johnson & Johnson	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Arrhythmias and Clinical EP</i>
Medicare, Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Acute Coronary Syndromes</i>
Pfizer, Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Arrhythmias and Clinical EP</i>
PhaseBio	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Other</i>
Portola Pharmaceuticals, Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
Salix Pharmaceuticals, Ltd	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Other</i>

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

## Agreement

**Certified Education Attestation** | Signed on 10/13/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 10/13/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

**Embargo** | Signed on 10/13/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

**On-Going Obligation Agreement** | Signed on 10/13/2023

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.